Literature DB >> 10386258

Antimicrobial resistance in intensive care units.

S K Fridkin1, R P Gaynes.   

Abstract

The unique nature of the intensive care unit (ICU) environment makes this part of the hospital a focus for the emergence and spread of many antimicrobial-resistant pathogens. There are ample opportunities for the cross-transmission of resistant bacteria from patient to patient, and patients are commonly exposed to broad-spectrum antimicrobial agents. Rates of resistance have increased for most pathogens associated with nosocomial infections among ICU patients, and rates are almost universally higher among ICU patients compared with non-ICU patients. There are many opportunities, however, to prevent the emergence and spread of these resistant pathogens through improved use of established infection control measures (i.e., patient isolation, hand washing, glove use, and appropriate gown use), and implementation of a systematic review of antimicrobial use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386258     DOI: 10.1016/s0272-5231(05)70143-x

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  44 in total

1.  A new TEM-derived extended-spectrum beta-lactamase (TEM-91) with an R164C substitution at the omega-loop confers ceftazidime resistance.

Authors:  Hiroshi Kurokawa; Naohiro Shibata; Yohei Doi; Keigo Shibayama; Kazunari Kamachi; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

2.  Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria.

Authors:  E Raineri; L Crema; S Dal Zoppo; A Acquarolo; A Pan; G Carnevale; F Albertario; A Candiani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

3.  Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel.

Authors:  Jacob Schlesinger; Shiri Navon-Venezia; Inna Chmelnitsky; Orly Hammer-Münz; Azita Leavitt; Howard S Gold; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Genome-wide identification of Pseudomonas aeruginosa exported proteins using a consensus computational strategy combined with a laboratory-based PhoA fusion screen.

Authors:  Shawn Lewenza; Jennifer L Gardy; Fiona S L Brinkman; Robert E W Hancock
Journal:  Genome Res       Date:  2005-02       Impact factor: 9.043

5.  Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Authors:  Pieter Depuydt; Dominique Benoit; Dirk Vogelaers; Geert Claeys; Gerda Verschraegen; Koenraad Vandewoude; Johan Decruyenaere; Stijn Blot
Journal:  Intensive Care Med       Date:  2006-09-16       Impact factor: 17.440

6.  A new category--healthcare-associated pneumonia: a good idea, but problems with its execution.

Authors:  S Fujitani; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-10       Impact factor: 3.267

7.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 8.  Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs.

Authors:  Günter Kampf; Axel Kramer
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study.

Authors:  A Acquarolo; T Urli; G Perone; C Giannotti; A Candiani; N Latronico
Journal:  Intensive Care Med       Date:  2005-03-08       Impact factor: 17.440

10.  Methicillin-resistant Staphylococcus non-aureus infection in an irradiated rhesus macaque (Macaca mulatta).

Authors:  Krishnan Kolappaswamy; Steven T Shipley; Ivan I Tatarov; Louis J DeTolla
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-05       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.